Alain obtained his PhD in Molecular Biology from the medical faculty of Laval University (Quebec City) in 1992. Following a postdoctoral fellowship, he started to transition to biopharma by joining first the National Research council lab and then a small start-up company developing pain drugs. He then joined a respiratory-oriented biotech, where he first worked as a team leader, rising to Project Manager on the drug development team. Reporting to the VP of Drug Development, he gained significant hands-on drug development experience by managing all outsourced drug development activities including CMC, method development, toxicology studies, Phase 1 clinical trials, and supporting activities.
He then joined Premier Partners in his initial role, which involved the management of several nonclinical programs for a variety of clients. Alain gained experience with various types of drugs including small molecules, oligonucleotides, RNA, proteins, and biologics, and with multiple routes of administration and formulation such as inhalation (dry powder, liquid aerosols), intravenous, intravitreal, subcutaneous, and oral.
In 2011, he founded one of the Premier Partners R&D companies, which is responsible for managing multiple IND-enabling toxicology programs and Phase 1 clinical studies in different therapeutic indications. He focuses on helping sponsors plan, execute, monitor, and/or manage their development programs to facilitate successful regulatory submissions and initiate clinical activities.